RET and thyroid cancer: Additionally, treatment with pralsetinib resulted in 60% (95%Cl 46–73) in patients who had previously received targeted therapy and 60% (95%Cl 46–73) with ORR in patients with RET fusion-positive thyroid cancer [74].